[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573152":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":26,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":26,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":49,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"National Institute of Cardiovascular Diseases, Pakistan","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Study arm (Apixaban 2.5 mg bid)","EXPERIMENTAL","Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT. o In the event of stent thrombosis during the study period, considering the high ischemic risk, the patient will be switched to ticagrelor instead of clopidogrel, and aspirin will be discontinued while Apixaban will be continued. After four weeks, the patient will be switched to DAPT (aspirin\n\n\\+ ticagrelor).",[13],"Drug: Apixaban 2.5 MG PO BID",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","ACTIVE_COMPARATOR","The control arm will be of standard care i.e. DAPT in addition to other guideline directed medical therapy (GDMT).",[19],"Drug: Control (Standard treatment)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Apixaban 2.5 MG PO BID","Patients randomized to the treatment arm will be given Apixaban 2.5 mg twice daily and DAPT (aspirin (75 mg) + clopidogrel (75 mg)) for four weeks in addition to other guideline directed medical therapy (GDMT). After 4 weeks, treatment group will be switched to DAPT.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Control (Standard treatment)","DAPT plus guideline directed medical therapy",[15],[32],{"name":33,"affiliation":34,"role":35},"Abdul Hakeem Professor of Cardiology, Director Cardiac Catheterization Labs, MD FACC FSCAI FASE","NICVD","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Abdul Hakeem, MD FACC FSCAI FASE","CONTACT","+92 3355554342","ahakeem@gmail.com",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":45},"Sabha Bhatti, MD FASE FASNC FACC","608-772-3048","drsabhabhatti@gmail.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"NICVD Pakistan","RECRUITING","Karachi","Sindh","Pakistan","PK",{"type":55,"coordinates":56},"Point",[57,58],67.0104,24.8608,{"lat":58,"lon":57},[61],{"name":62,"role":39,"phone":63,"phoneExt":26,"email":41},"Abdul Hakeem, MD","+92 21 99201271",{"type":35,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Professor Abdul Hakeem","professor","100573152","phase-3-apixaban-prophylaxis-for-prevention-of-left-ventricular-thrombus-following-anterior-myocardial-infarction-100573152",false,"NCT06742567","Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction: An Open Label, Randomized Clinical Trial (POTAMI)","POTAMI","Inclusion Criteria:\n\n* Patients aged 18-65 years\n* Presenting with acute anterior STEMI\n* Severe LV dysfunction (EF\\\u003C35%) with antero-apical akinesis, dyskinesis, or aneurysm\n* WIHTOUT evidence of LV thrombus.\n\nExclusion Criteria:\n\n* Patients with previous anterior myocardial infarction or LAD revascularization procedures\n* Patients with cardiogenic shock\n* Patients with LV thrombus\n* Patients with advanced CKD (Cr \\> 2 and those on hemodialysis)\n* Recent ICH or major bleed requiring transfusion, low platelet counts \\\u003C100,000\n* History of recent CVA ( within past three months)\n* Patients with atrial fibrillation or other indications for chronic anticoagulation\n* Pregnant patients and those with hematological disorders","ALL","18 Years","75 Years",{"count":79,"type":80},472,"ESTIMATED","INTERVENTIONAL",[83],"PHASE3","The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.",[86,87,88],"Acute Myocardial Infarction of Anterior Wall","Left Ventricular Thrombus","Prophylaxis",[90,91,92,93,94],"Acute myocardial infarction","severe left ventricular dysfunction","prevention of LV thrombus","DOAC","apixaban","2024-12-17",{"date":97,"type":98},"2024-12-19","ACTUAL",{"date":100,"type":98},"2024-12-02",{"date":102,"type":80},"2025-11-30",{"name":5,"class":6},1]